BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 23672185)

  • 21. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
    Salmi-Smail C; Fabre A; Dequiedt F; Restouin A; Castellano R; Garbit S; Roche P; Morelli X; Brunel JM; Collette Y
    J Med Chem; 2010 Apr; 53(8):3038-47. PubMed ID: 20218673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni.
    Stenzel K; Chakrabarti A; Melesina J; Hansen FK; Lancelot J; Herkenhöhner S; Lungerich B; Marek M; Romier C; Pierce RJ; Sippl W; Jung M; Kurz T
    Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28639720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
    Tang G; Wong JC; Zhang W; Wang Z; Zhang N; Peng Z; Zhang Z; Rong Y; Li S; Zhang M; Yu L; Feng T; Zhang X; Wu X; Wu JZ; Chen L
    J Med Chem; 2014 Oct; 57(19):8026-34. PubMed ID: 25238284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R; Wang J; Tang W; Fang H
    Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
    Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
    Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
    Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.